Summary & Overview
HCPCS Level II M1311: Anaphylaxis Due to Vaccine, Acute Care
HCPCS Level II code M1311 identifies care related to anaphylaxis due to the vaccine on or before the date of the encounter, signaling an acute, potentially life-threatening allergic reaction temporally linked to vaccination. Nationally, accurate use of this code matters for clinical tracking, safety surveillance, quality reporting, and appropriate claim adjudication for acute vaccine-related adverse events. It is relevant across emergency and urgent care settings where immediate management and documentation occur.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context and service settings tied to M1311, plus what to expect in payer coverage patterns and coding practice considerations. The publication summarizes typical sites of service, common modifiers reported with similar acute care codes, and where data is unavailable.
This piece provides benchmarks and policy-relevant context for billing and claims teams, hospital compliance officers, and payers responsible for adjudicating vaccine-related adverse event claims. It highlights the importance of precise coding to support patient safety surveillance, reimbursement alignment, and downstream reporting without providing clinical guidance or recommendations.
Billing Code Overview
HCPCS Level II code M1311 denotes anaphylaxis due to the vaccine on or before the date of the encounter. This code represents a documented acute allergic reaction triggered by a vaccine that occurred on or before the recorded encounter date.
Service Type: Acute allergic reaction / anaphylaxis management
Typical Site of Service: Emergency department, urgent care, or other acute care settings
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A patient presents to an outpatient vaccination clinic or emergency department immediately after receiving a vaccine and develops signs of an acute hypersensitivity reaction consistent with anaphylaxis. Typical onset is within minutes to one hour of vaccine administration and may include respiratory distress (wheezing, stridor), hypotension or syncope, generalized urticaria, angioedema, nausea, vomiting, or altered mental status. The clinical workflow includes immediate assessment of airway, breathing, and circulation; administration of intramuscular epinephrine as first-line therapy; supplemental oxygen, intravenous access, and fluid resuscitation as needed; adjunctive therapies such as antihistamines and corticosteroids; and observation for biphasic reactions. Documentation must record the vaccine administered, time of administration, onset and progression of symptoms, treatments given (medication name, dose, route, and time), response to treatment, and disposition (discharge with observation instructions or admission). The billing code M1311 is used to indicate an encounter where anaphylaxis due to the vaccine occurred on or before the date of the encounter. Typical sites of service include outpatient vaccination clinics, primary care offices, urgent care centers, and emergency departments. A realistic patient scenario: a 28-year-old receiving an influenza or COVID-19 vaccine in a community clinic develops throat tightness, facial swelling, hypotension, and diffuse hives within 15 minutes; the clinician documents onset time, administers epinephrine IM, provides oxygen and IV fluids, observes response, and records the vaccine lot and patient counseling before discharging to the patient with follow-up instructions or admits if unstable.
Coding Specifications
| Modifier | Description |
|---|